

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



碧生源控股有限公司
BESUNYEN HOLDINGS COMPANY LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 926)

**CHANGE OF PRODUCT NAME FOR SLIMMING TEA PRODUCT
AND
PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions under Part XIVA of the SFO.

The Board hereby announces that on 15 November 2016, the Group received the Approval from the CFDA pursuant to which the product name is approved to change from “碧生源牌減肥茶” to “碧生源牌常菁茶”. After obtaining the new Food Production Permit, the Group’s slimming tea products with the new name in new packages is expected to resume manufacture and sell in December 2016.

Nevertheless, based on the preliminary estimate on the unaudited consolidated management accounts of the Group, the Board hereby informs the shareholders and potential investors of the Company, it is expected that the Group may record a net loss attributable to the shareholders of the Company of approximately RMB50 million to RMB70 million for the year 2016. This is mainly attributable to: (i) the manufacture of the Group’s slimming tea products has been suspended for more than half a year due to delay in obtaining the Approval, the slimming tea products in sale are out of stock in some sales regions, thereby having affected the sale of the slimming tea products; (ii) the relevant selling and marketing expenses of the slimming medicine Orlistat under the brand of “LARLLY” for the year 2016 are expected to increase significantly as compared to that for the year 2015. The management of the Group will endeavour to devote to the manufacture and sale of the slimming tea products after the change of name, and expects that next year’s operations will resume to normal.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Besunyen Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Reference is made to (i) the announcements dated 2 September 2015 and 27 May 2016 of the Company in relation to, among others, the Group’s application for changing the product name of its slimming tea product, in order to meet the relevant requirements on the product name of healthcare food issued by China Food and Drug Administration (the “**CFDA**”); and (ii) the 2016 Interim Report of the Company published on 12 September 2016 in relation to, among others, the submissions of the applications for the change of product name “碧生源牌減肥茶” to the CFDA on 30 December 2015 and thereafter by the Company, and the promotion of faster completion of the change of product name “碧生源牌減肥茶” in the second half of 2016.

Further to the announcements dated 2 September 2015 and 27 May 2016 and the 2016 Interim Report of the Company, the board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that on 15 November 2016, the Group received the approval for the change of domestic healthcare food in relation to “碧生源牌常菁茶” from the CFDA (the “**Approval**”) pursuant to which the product name is approved to change from “碧生源牌減肥茶” to “碧生源牌常菁茶”. There was no reference to the English product name in the content of the Approval, the English product name of the slimming tea product remains unchanged, being “Besunyen Slimming Tea”. Apart from the change of Chinese product name, there is no change to the healthcare function, healthcare food serial number, production process and formula, raw materials, ingredients and flavour, specification of formulation and content of product brochure of such slimming tea product. In addition, slimming tea products manufactured before the end of 2016 are allowed to be named as “碧生源牌常菁茶(原碧生源牌減肥茶)” on their external packages, product brochures and relevant advertising materials, according to the relevant regulatory requirements.

Upon receipt of the Approval, the Group is required to renew the Food Production Permit in relation to the manufacture and operation of the slimming tea product according to the relevant regulatory requirements. After obtaining the new Food Production Permit, the Group’s slimming tea products with the new name in new packages is expected to resume manufacture and sell in December 2016.

Nevertheless, based on the preliminary estimate on the unaudited consolidated management accounts of the Group, the Board hereby informs the shareholders and potential investors of the Company, it is expected that the Group may record a net loss attributable to the shareholders of the Company of approximately RMB50 million to RMB70 million for the year 2016. This is mainly attributable to: (i) the manufacture of the Group’s slimming tea products has been suspended for more than half a year due to delay in obtaining the Approval, the slimming tea products in sale are out of stock in some sales regions, thereby having affected the sale of the slimming tea products; (ii) the relevant selling and marketing expenses of the slimming medicine Orlistat under the brand of “LARLLY” for the year 2016 are expected to increase significantly as compared to that for the year 2015. The management of the Group will endeavour to devote to the manufacture and sale of the slimming tea products after the change of name, and expects that next year’s operations will resume to normal.

As year 2016 has not yet ended, the annual results of the Group for the year ending 31 December 2016 have not been finalised. The information contained in this announcement represents the preliminary estimate by the management of the Company with reference to the consolidated management accounts of the Group, which have not been audited or reviewed by the auditor of the Company. Specific and accurate financial information will be disclosed in the annual results announcement of the Company for the year ending 31 December 2016, which will be published by the Company in March 2017.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Besunyen Holdings Company Limited
Zhao Yihong
Chairman and Chief Executive Officer

Hong Kong, 16 November 2016

As at the date of this announcement, the executive Directors are Mr. Zhao Yihong (Chairman and Chief Executive Officer) and Ms. Gao Yan (Vice Chairman); the non-executive Directors are Mr. Zhuo Fumin and Ms. Zhang Guimei; and the independent non-executive Directors are Mr. Huang Jingsheng, Mr. Ren Guangming and Mr. He Yuanping.